A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model

Human Molecular Genetics

Volumn 21, Issue 6, 2012, Pages 1230-1247

  Vyas, Piyush M ^a   Tomamichel, Wendy J ^a   Pride, P Melanie ^a   Babbey, Clifford M ^a   Wang, Qiujuan ^a   Mercier, Jennifer ^b   Martin, Elizabeth M ^a   Payne, R Mark ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; CASPASE 3; FRATAXIN; HYBRID PROTEIN; MITOCHONDRIA PROCESSING PEPTIDASE; MITOCHONDRIAL ENZYME; TAT FRATAXIN FUSION PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA FLOW; APOPTOSIS; ARTICLE; ASCENDING AORTA; BLOOD FLOW VELOCITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FIBROBLAST; FRIEDREICH ATAXIA; GENE DELIVERY SYSTEM; GROWTH RATE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE DIAMETER; HEART LEFT VENTRICLE POSTERIOR WALL THICKNESS; HEART MUSCLE CELL; HEART OUTPUT; HEART RATE; HEART VENTRICLE SIZE; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; KNOCKOUT MOUSE; LIFESPAN; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN LOCALIZATION; SURVIVAL RATE;

ACONITATE HYDRATASE; ANIMALS; CASPASE 3; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FRIEDREICH ATAXIA; GENE PRODUCTS, TAT; HEART; HUMANS; INTEGRASES; IRON; IRON-BINDING PROTEINS; LONGEVITY; MALE; MICE; MICE, KNOCKOUT; MITOCHONDRIA; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TRANS-ACTIVATORS;

MUS;

EID: 84863278400     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr554     Document Type: Article

References (99)

1. Harding, A.E. (1981) Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain, 104, 589-620.
2. Malo, S., Latour, Y., Cote, M., Geoffroy, G., Lemieux, B. and Barbeau, A. (1976) Electrocardiographic and vectocardiographic findings in Friedreich's ataxia. Can. J. Neurol. Sci., 3, 323-328.
3. Tsou, A.Y., Paulsen, E.K., Lagedrost, S.J., Perlman, S.L., Mathews, K.D., Wilmot, G.R., Ravina, B., Koeppen, A.H. and Lynch, D.R. (2011) Mortality in friedreich ataxia. J. Neurol. Sci., 307, 46-49.
4. Schols, L., Amoiridis, G., Przuntek, H., Frank, G., Epplen, J.T. and Epplen, C. (1997) Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain, 120 (Pt 12), 2131-2140.
5. Filla, A., De Michele, G., Marconi, R., Bucci, L., Carillo, C., Castellano, A.E., Iorio, L., Kniahynicki, C., Rossi, F. and Campanella, G. (1992) Prevalence of hereditary ataxias and spastic paraplegias in Molise, a region of Italy. J. Neurol., 239, 351-353.
6. Romeo, G., Menozzi, P., Ferlini, A., Fadda, S., Di Donato, S., Uziel, G., Lucci, B., Capodaglio, L., Filla, A. and Campanella, G. (1983) Incidence of Friedreich ataxia in Italy estimated from consanguineous marriages. Am. J. Hum. Genet., 35, 523-529.
7. Skre, H. (1975) Friedreich's ataxia in Western Norway. Clin. Genet., 7, 287-298.
8. Epplen, C., Epplen, J.T., Frank, G., Miterski, B., Santos, E.J. and Schols, L. (1997) Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum. Genet., 99, 834-836.
9. Pandolfo, M. (2008) Friedreich ataxia. Arch. Neurol., 65, 1296-1303.
10. Patel, P.I. and Isaya, G. (2001) Friedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency. Am. J. Hum. Genet., 69, 15-24.
11. Gacy, A.M., Goellner, G.M., Spiro, C., Chen, X., Gupta, G., Bradbury, E.M., Dyer, R.B., Mikesell, M.J., Yao, J.Z., Johnson, A.J. et al. (1998) GAA instability in Friedreich's Ataxia shares a common, DNA-directed and intraallelic mechanism with other trinucleotide diseases. Mol. Cell., 1, 583-593.
12. Sakamoto, N., Ohshima, K., Montermini, L., Pandolfo, M. and Wells, R.D. (2001) Sticky DNA, a self-associated complex formed at long GAA * TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J. Biol. Chem., 276, 27171-27177.
13. Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S.L. and Gottesfeld, J.M. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol., 2, 551-558.
14. Montermini, L., Richter, A., Morgan, K., Justice, C.M., Julien, D., Castellotti, B., Mercier, J., Poirier, J., Capozzoli, F., Bouchard, J.P. et al. (1997) Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann. Neurol., 41, 675-682.
15. Filla, A., De Michele, G., Cavalcanti, F., Pianese, L., Monticelli, A., Campanella, G. and Cocozza, S. (1996) The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am. J. Hum. Genet., 59, 554-560.
16. Zhang, Y., Lyver, E.R., Knight, S.A., Pain, D., Lesuisse, E. and Dancis, A. (2006) Mrs3p, Mrs4p, and frataxin provide iron for Fe-S cluster synthesis in mitochondria. J. Biol. Chem., 281, 22493-22502.
17. Huang, M.L., Becker, E.M., Whitnall, M., Rahmanto, Y.S., Ponka, P. and Richardson, D.R. (2009) Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc. Natl Acad. Sci. USA, 106, 16381-16386.
18. Yoon, T. and Cowan, J.A. (2004) Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biol. Chem., 279, 25943-25946.
19. Correia, A.R., Wang, T., Craig, E.A. and Gomes, C.M. (2010) Iron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge region. Biochem. J., 426, 197-203.
20. Tsai, C.L. and Barondeau, D.P. (2010) Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex. Biochemistry, 49, 9132-9139.
21. Stemmler, T.L., Lesuisse, E., Pain, D. and Dancis, A. (2010) Frataxin and mitochondrial FeS cluster biogenesis. J. Biol. Chem., 285, 26737-26743.
22. Schmucker, S., Martelli, A., Colin, F., Page, A., Wattenhofer-Donze, M., Reutenauer, L. and Puccio, H. (2011) Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS One, 6, e16199.
23. Rotig, A., de Lonlay P., Chretien, D., Foury, F., Koenig, M., Sidi, D., Munnich, A. and Rustin, P. (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet., 17, 215-217.
24. Lodi, R., Cooper, J.M., Bradley, J.L., Manners, D., Styles, P., Taylor, D.J. and Schapira, A.H. (1999) Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA, 96, 11492-11495.
25. Lodi, R., Rajagopalan, B., Blamire, A.M., Cooper, J.M., Davies, C.H., Bradley, J.L., Styles, P. and Schapira, A.H. (2001) Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovasc. Res., 52, 111-119.
26. Gakh, O., Cavadini, P. and Isaya, G. (2002) Mitochondrial processing peptidases. Biochim. Biophys. Acta, 1592, 63-77.
27. Cavadini, P., Adamec, J., Taroni, F., Gakh, O. and Isaya, G. (2000) Two-step processing of human frataxin by mitochondrial processing peptidase. Precursor and intermediate forms are cleaved at different rates. J. Biol. Chem., 275, 41469-41475.
28. Condo, I., Ventura, N., Malisan, F., Rufini, A., Tomassini, B. and Testi, R. (2007) In vivo maturation of human frataxin. Hum. Mol. Genet., 16, 1534-1540.
29. Schmucker, S., Argentini, M., Carelle-Calmels, N., Martelli, A. and Puccio, H. (2008) The in vivo mitochondrial two-step maturation of human frataxin. Hum. Mol. Genet., 17, 3521-3531.
30. Richardson, D.R. (2003) Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert. Opin. Investig. Drugs, 12, 235-245.
31. Jauslin, M.L., Meier, T., Smith, R.A. and Murphy, M.P. (2003) Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J., 17, 1972-1974.
32. Hart, P.E., Lodi, R., Rajagopalan, B., Bradley, J.L., Crilley, J.G., Turner, C., Blamire, A.M., Manners, D., Styles, P., Schapira, A.H. et al. (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol., 62, 621-626.
33. Puccio, H., Simon, D., Cossee, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P. and Koenig, M. (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet., 27, 181-186.
34. Schwarze, S.R., Ho, A., Vocero-Akbani, A. and Dowdy, S.F. (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 285, 1569-1572.
35. Del Gaizo-Moore, V., MacKenzie, J.A. and Payne, R.M. (2003) Targeting proteins to mitochondria using TAT. Mol. Genet. Metab, 80, 170-180.
36. Zhang, X.Y., Dinh, A., Cronin, J., Li, S.C. and Reiser, J. (2008) Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain. J. Neurochem., 104, 1055-1064.
37. Jensen, K.D., Nori, A., Tijerina, M., Kopeckova, P. and Kopecek, J. (2003) Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J. Control. Release, 87, 89-105.
38. Del Gaizo, V. and Payne, R.M. (2003) A novel TAT-Mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol. Ther., 7, 720-730.
39. Mishra, A., Lai, G.H., Schmidt, N.W., Sun, V.Z., Rodriguez, A.R., Tong, R., Tang, L., Cheng, J., Deming, T.J., Kamei, D.T. et al. (2011) Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc. Natl. Acad. Sci. U.S.A., 108, 16883-16888.
40. Rapoport, M., Salman, L., Sabag, O., Patel, M.S. and Lorberboum-Galski, H. (2011) Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency. J. Mol. Med., 89, 161-170.
41. Toro, A. and Grunebaum, E. (2006) TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J. Clin. Invest., 116, 2717-2726.
42. Pendergrass, W., Wolf, N. and Poot, M. (2004) Efficacy of MitoTracker Green and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues. Cytometry A, 61, 162-169.
43. Poot, M., Zhang, Y.Z., Kramer, J.A., Wells, K.S., Jones, L.J., Hanzel, D.K., Lugade, A.G., Singer, V.L. and Haugland, R.P. (1996) Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. J. Histochem. Cytochem., 44, 1363-1372.
44. Adamec, J., Gakh, O., Spizek, J. and Kalousek, F. (1999) Complementation between mitochondrial processing peptidase (MPP) subunits from different species. Arch. Biochem. Biophys., 370, 77-85.
45. Chu, T.W., Eftime, R., Sztul, E. and Strauss, A.W. (1989) Synthetic transit peptides inhibit import and processing of mitochondrial precursor proteins. J. Biol. Chem., 264, 9552-9558.
46. Sztul, E.S., Chu, T.W., Strauss, A.W. and Rosenberg, L.E. (1988) Import of the malate dehydrogenase precursor by mitochondria. Cleavage within leader peptide by matrix protease leads to formation of intermediate-sized form. J. Biol. Chem., 263, 12085-12091.
47. Isaya, G., Kalousek, F., Fenton, W.A. and Rosenberg, L.E. (1991) Cleavage of precursors by the mitochondrial processing peptidase requires a compatible mature protein or an intermediate octapeptide. J. Cell. Biol., 113, 65-76.
48. Lu, C. and Cortopassi, G. (2007) Frataxin knockdown causes loss of cytoplasmic iron-sulfur cluster functions, redox alterations and induction of heme transcripts. Arch. Biochem. Biophys., 457, 111-122.
49. Bulteau, A.L., O'Neill, H.A., Kennedy, M.C., Ikeda-Saito, M., Isaya, G. and Szweda, L.I. (2004) Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science, 305, 242-245.
50. Mordente, A., Martorana, G.E., Minotti, G. and Giardina, B. (1998) Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Chem. Res. Toxicol., 11, 54-63.
51. Gillner, M., Moore, G.S., Cederberg, H. and Gustafsson, K. (1994) Hydroquinone (environmental Health Criteria, No 157). World Health Organization, Geneva, Switzerland.
52. Pastore, C., Franzese, M., Sica, F., Temussi, P. and Pastore, A. (2007) Understanding the binding properties of an unusual metal-binding protein-a study of bacterial frataxin. Febs J, 274, 4199-4210.
53. Radisky, D.C., Babcock, M.C. and Kaplan, J. (1999) The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J. Biol. Chem., 274, 4497-4499.
54. Foury, F. and Cazzalini, O. (1997) Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett., 411, 373-377.
55. Wong, A., Yang, J., Cavadini, P., Gellera, C., Lonnerdal, B., Taroni, F. and Cortopassi, G. (1999) The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet., 8, 425-430.
56. Lin, F. and Girotti, A.W. (1997) Elevated ferritin production, iron containment, and oxidant resistance in hemin-treated leukemia cells. Arch. Biochem. Biophys., 346, 131-141.
57. Oubidar, M., Marie, C., Mossiat, C. and Bralet, J. (1996) Effects of increasing intracellular reactive iron level on cardiac function and oxidative injury in the isolated rat heart. J. Mol. Cell. Cardiol., 28, 1769-1776.
58. Sogabe, K., Roeser, N.F., Venkatachalam, M.A. and Weinberg, J.M. (1996) Differential cytoprotection by glycine against oxidant damage to proximal tubule cells. Kidney Int., 50, 845-854.
59. Balla, G., Vercellotti, G.M., Eaton, J.W. and Jacob, H.S. (1990) Iron loading of endothelial cells augments oxidant damage. J. Lab. Clin. Med., 116, 546-554.
60. Cossee, M., Puccio, H., Gansmuller, A., Koutnikova, H., Dierich, A., LeMeur, M., Fischbeck, K., Dolle, P. and Koenig, M. (2000) Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet., 9, 1219-1226.
61. Cinato, E., Mirotsou, M. and Sablitzky, F. (2001) Cre-mediated transgene activation in the developing and adult mouse brain. Genesis, 31, 118-125.
62. El Sharaby, A.A., Egerbacher, M., Hammoda, A.K. and Bock, P. (2001) Immunohistochemical demonstration of Leu-7 (HNK-1), Neurone-specific Enolase (NSE) and Protein-Gene Peptide (PGP) 9.5 in the developing camel (Camelus dromedarius) heart. Anat. Histol. Embryol., 30, 321-325.
63. Semba, R., Asano, T. and Kato, K. (1990) Physiological expression of neural marker proteins in the heart of young rats. Brain Res. Dev. Brain Res., 54, 217-220.
64. Bland, J.M. and Altman, D.G. (2004) The logrank test. Br. Med. J., 328, 1073.
65. Patel, A.L., Engstrom, J.L., Meier, P.P. and Kimura, R.E. (2005) Accuracy of methods for calculating postnatal growth velocity for extremely low birth weight infants. Pediatrics, 116, 1466-1473.
66. Stehling, O., Elsasser, H.P., Bruckel, B., Muhlenhoff, U. and Lill, R. (2004) Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum. Mol. Genet., 13, 3007-3015.
67. Whitnall, M., Rahmanto, Y.S., Sutak, R., Xu, X., Becker, E.M., Mikhael, M.R., Ponka, P. and Richardson, D.R. (2008) The MCK mouse heart model of Friedreich's ataxia: alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc. Natl Acad. Sci. USA, 105, 9757-9762.
68. Seznec, H., Simon, D., Bouton, C., Reutenauer, L., Hertzog, A., Golik, P., Procaccio, V., Patel, M., Drapier, J.C., Koenig, M. et al. (2005) Friedreich ataxia: the oxidative stress paradox. Hum. Mol. Genet., 14, 463-474.
69. Martelli, A., Wattenhofer-Donze, M., Schmucker, S., Bouvet, S., Reutenauer, L. and Puccio, H. (2007) Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum. Mol. Genet., 16, 2651-2658.
70. Lill, R. and Muhlenhoff, U. (2008) Maturation of iron-sulfur proteins in eukaryotes: mechanisms, connected processes, and diseases. Annu. Rev. Biochem., 77, 669-700.
71. Noble, R.J. and Nutter, D.O. (1970) The demonstration of alternating contractile state in pulsus alternans. J. Clin. Invest., 49, 1166-1177.
72. Ho, C.Y. (2007) Echocardiographic assessment of diastolic function. In Solomon, S.D. and Bulwer, B.E. (eds), Essential Echocardiography: A Practical Handbook. Humana Press, New York, pp. 119-131.
73. Dutka, D.P., Donnelly, J.E., Palka, P., Lange, A., Nunez, D.J. and Nihoyannopoulos, P. (2000) Echocardiographic characterization of cardiomyopathy in Friedreich's ataxia with tissue Doppler echocardiographically derived myocardial velocity gradients. Circulation, 102, 1276-1282.
74. Laguens, R.P. and Gomez-Dumm, C.L. (1967) Fine structure of myocardial mitochondria in rats after exercise for one-half to two hours. Circ. Res., 21, 271-279.
75. Laguens, R.P., Weinschelbaun, R. and Favaloro, R. (1979) Ultrastructural and morphometric study of the human heart muscle cell in acute coronary insufficiency. Hum. Pathol., 10, 695-705.
76. Zhu, W., Soonpaa, M.H., Chen, H., Shen, W., Payne, R.M., Liechty, E.A., Caldwell, R.L., Shou, W. and Field, L.J. (2009) Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation, 119, 99-106.
77. Morvan, D., Komajda, M., Doan, L.D., Brice, A., Isnard, R., Seck, A., Lechat, P., Agid, Y. and Grosgogeat, Y. (1992) Cardiomyopathy in Friedreich's ataxia: a Doppler-echocardiographic study. Eur. Heart. J., 13, 1393-1398.
78. Mottram, P.M., Delatycki, M.B., Donelan, L., Gelman, J.S., Corben, L. and Peverill, R.E. (2011) Early changes in left ventricular long-axis function in Friedreich ataxia: relation with the FXN gene mutation and cardiac structural change. J. Am. Soc. Echocardiogr., 24, 782-789.
79. Regner, S.R., Lagedrost, S.J., Plappert, T., Paulsen, E.K., Friedman, L.S., Snyder, M.L., Perlman, S.L., Mathews, K.D., Wilmot, G.R., Schadt, K.A. et al. (2011) Analysis of Echocardiograms in a Large Heterogeneous Cohort of Patients with Friedreich Ataxia. Am. J. Cardiol. [Epub ahead of print].
80. Wallace, D.C. (1999) Mitochondrial diseases in man and mouse. Science, 283, 1482-1488.
81. Neupert, W. and Herrmann, J.M. (2007) Translocation of proteins into mitochondria. Annu. Rev. Biochem., 76, 723-749.
82. Gobbi, H., Barbosa, A.J., Teixeira, V.P. and Almeida, H.O. (1991) Immunocytochemical identification of neuroendocrine markers in human cardiac paraganglion-like structures. Histochemistry, 95, 337-340.
83. Pearce, J.M., Edwards, Y.H. and Harris, H. (1976) Human enolase isozymes: electrophoretic and biochemical evidence for three loci. Ann. Hum. Genet., 39, 263-276.
84. Skowasch, D., Jabs, A., Andrie, R., Dinkelbach, S., Luderitz, B. and Bauriedel, G. (2003) Presence of bone-marrow- and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis. Cardiovasc. Res., 60, 684-691.
85. Haimoto, H., Takahashi, Y., Koshikawa, T., Nagura, H. and Kato, K. (1985) Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab. Invest., 52, 257-263.
86. Forss-Petter, S., Danielson, P.E., Catsicas, S., Battenberg, E., Price, J., Nerenberg, M. and Sutcliffe, J.G. (1990) Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron, 5, 187-197.
87. Frugier, T., Tiziano, F.D., Cifuentes-Diaz, C., Miniou, P., Roblot, N., Dierich, A., Le, M.M. and Melki, J. (2000) Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum. Mol. Genet., 9, 849-858.
88. Quercia, N., Somers, G.R., Halliday, W., Kantor, P.F., Banwell, B. and Yoon, G. (2010) Friedreich ataxia presenting as sudden cardiac death in childhood: clinical, genetic and pathological correlation, with implications for genetic testing and counselling. Neuromuscul. Disord., 20, 340-342.
89. Campuzano, V., Montermini, L., Lutz, Y., Cova, L., Hindelang, C., Jiralerspong, S., Trottier, Y., Kish, S.J., Faucheux, B., Trouillas, P. et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet., 6, 1771-1780.
90. Ye, N., Liu, S., Lin, Y. and Rao, P. (2011) Protective effects of intraperitoneal injection of TAT-SOD against focal cerebral ischemia/reperfusion injury in rats. Life Sciences, 89, 868-874.
91. Asoh, S., Ohsawa, I., Mori, T., Katsura, K., Hiraide, T., Katayama, Y., Kimura, M., Ozaki, D., Yamagata, K. and Ohta, S. (2002) Protection against ischemic brain injury by protein therapeutics. Proc. Natl Acad. Sci. USA, 99, 17107-17112.
92. Cao, G., Pei, W., Ge, H., Liang, Q., Luo, Y., Sharp, F.R., Lu, A., Ran, R., Graham, S.H. and Chen, J. (2002) In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci., 22, 5423-5431.
93. Kim, D.W., Eum, W.S., Jang, S.H., Kim, S.Y., Choi, H.S., Choi, S.H., An, J.J., Lee, S.H., Lee, K.S., Han, K. et al. (2005) Transduced Tat-SOD fusion protein protects against ischemic brain injury. Mol. Cells, 19, 88-96.
94. Tan, G., Chen, L.S., Lonnerdal, B., Gellera, C., Taroni, F.A. and Cortopassi, G.A. (2001) Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum. Mol. Genet., 10, 2099-2107.
95. Grant, P.M., Roderick, S.L., Grant, G.A., Banaszak, L.J. and Strauss, A.W. (1987) Comparison of the precursor and mature forms of rat heart mitochondrial malate dehydrogenase. Biochemistry, 26, 128-134.
96. Grant, P.M., Tellam, J., May, V.L. and Strauss, A.W. (1986) Isolation and nucleotide sequence of a cDNA clone encoding rat mitochondrial malate dehydrogenase. Nucleic Acids Res., 14, 6053-6066.
97. Li, K., Besse, E.K., Ha, D., Kovtunovych, G. and Rouault, T.A. (2008) Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum. Mol. Genet., 17, 2265-2273.
98. Nakajima, H., Nakajima, H.O., Tsai, S.C. and Field, L.J. (2004) Expression of mutant p193 and p53 permits cardiomyocyte cell cycle reentry after myocardial infarction in transgenic mice. Circ. Res., 94, 1606-1614.
99. Gao, X.M., Agrotis, A., Autelitano, D.J., Percy, E., Woodcock, E.A., Jennings, G.L., Dart, A.M. and Du, X.J. (2003) Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression. Endocrinology, 144, 4097-4105.